A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol. 2012 Apr; 125(1):136-40.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents
California
Carcinosarcoma
Chicago
Disease-Free Survival
Drug Administration Schedule
Female
Genital Neoplasms, Female
Humans
Kaplan-Meier Estimate
Leiomyosarcoma
Middle Aged
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Treatment Outcome

authors with profiles

Gini Fleming